Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo.

We investigated the antiviral activity of Arbidol, an antiviral chemical compound, against Coxsackie virus B5 (CVB(5)) in vitro and in vivo. Arbidol not only prevented the cytopathic effect (CPE) of CVB(5), as demonstrated in an MTT colorimetric assay, when added during or after viral infection, with a 50% inhibitory concentration (IC(50)) from 2.66 to 6.62 microg/ml, but it also decreased the CVB(5)-RNA level in infected host cells, as shown in semi-quantitative RT-PCR. BALB/c mice were used as an animal model to test the Arbidol activity in vivo. Orally administered Arbidol at 50 mg/kg body weight/day (once a day) significantly reduced mean virus yields in the lungs and heart as well as mortality after infection for 6 days. Our results demonstrate that in vitro and in vivo infection with CVB(5) can be effectively treated by Arbidol.
AuthorsQiong Zhong, Zhanqiu Yang, Yuanyuan Liu, Haiying Deng, Hong Xiao, Liqiao Shi, Jing He
JournalArchives of virology (Arch Virol) Vol. 154 Issue 4 Pg. 601-7 ( 2009) ISSN: 1432-8798 [Electronic] Austria
PMID19291363 (Publication Type: Journal Article)
Chemical References
  • Antiviral Agents
  • Indoles
  • arbidol
  • Animals
  • Antiviral Agents (administration & dosage, pharmacology, therapeutic use)
  • Cell Line
  • Coxsackievirus Infections (drug therapy)
  • Enterovirus B, Human (drug effects)
  • Heart (virology)
  • Humans
  • Indoles (administration & dosage, pharmacology, therapeutic use)
  • Inhibitory Concentration 50
  • Lung (virology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: